Pharmacological or genetic inhibition of hypoxia signaling attenuates oncogenic RAS-induced cancer phenotypes.
Pharmacological or genetic inhibition of hypoxia signaling attenuates oncogenic RAS-induced cancer phenotypes.
复制标题
DOI:
10.1242/dmm.048953
复制
发表时间:
2022-02-01
影响因子:
4.3
通讯作者:
Han Z
中科院分区:
文献类型:
--
作者:
Zhu JY;Huang X;Fu Y;Wang Y;Zheng P;Liu Y;Han Z
Oncogenic Ras mutations are highly prevalent in hematopoietic malignancies. However, it is difficult to directly target oncogenic RAS proteins for therapeutic intervention. We have developed a Drosophila acute myeloid leukemia model induced by human KRASG12V, which exhibits a dramatic increase in myeloid-like leukemia cells. We performed both genetic and drug screens using this model. The genetic screen identified 24 candidate genes able to attenuate the oncogenic RAS-induced phenotype, including two key hypoxia pathway genes HIF1A and ARNT (HIF1B). The drug screen revealed that echinomycin, an inhibitor of HIF1A, can effectively attenuate the leukemia phenotype caused by KRASG12V. Furthermore, we showed that echinomycin treatment can effectively suppress oncogenic RAS-driven leukemia cell proliferation, using both human leukemia cell lines and a mouse xenograft model. These data suggest that inhibiting the hypoxia pathway could be an effective treatment approach and that echinomycin is a promising targeted drug to attenuate oncogenic RAS-induced cancer phenotypes. Summary: Hypoxia pathway inhibition, either genetically or pharmacologically, rescues RAS-induced oncogenesis in a Drosophila acute myeloid leukemia model, mouse xenograft model and human leukemia cells.
登录
查看更多内容
影响因子:
5.2
作者:
Huang X;Liu Y;Wang Y;Bailey C;Zheng P;Liu Y
通讯作者:
Liu Y
影响因子:
3.4
作者:
Beaupre, DM;Kurzrock, R
通讯作者:
Kurzrock, R
影响因子:
11.2
作者:
Babij, Carol;Zhang, Yihong;Dussault, Isabelle
通讯作者:
Dussault, Isabelle
影响因子:
64.8
作者:
Dar, Arvin C.;Das, Tirtha K.;Shokat, Kevan M.;Cagan, Ross L.
通讯作者:
Cagan, Ross L.
影响因子:
4.7
作者:
Deynoux M;Sunter N;Hérault O;Mazurier F
通讯作者:
Mazurier F